Showing results (61-70 of 228) with videos related to
Sort By:
Pageof 23
Journal of the American Academy of Dermatology|November 15, 2017
Unrelated immunodeficiency states may impact outcomes and immune checkpoint molecule expression in patients with mycosis fungoides: A clinicopathologic case-control studyShay Warren, Meenal Kheterpal, Patricia L Myskowski, et al.Pathology|November 14, 2014
Mycosis fungoides with large cell transformation: clinicopathological features and prognostic factorsMelissa Pulitzer, Patricia L Myskowski, Steven M Horwitz, et al.The Journal of Dermatological Treatment|September 25, 2018
Treatment of Rosai-Dorfman disease with oral bexarotene: a case seriesShamir Geller, Klaus Busam, Paul A Hamlin, et al.American Journal of Hematology|July 12, 2021
Romidepsin and lenalidomide-based regimens have efficacy in relapsed/refractory lymphoma: Combined analysis of two phase I studies with expansion cohortsNeha Mehta-Shah, Matthew A Lunning, Alison J Moskowitz, et al.The Lancet. Oncology|November 1, 2024
Valemetostat for patients with relapsed or refractory peripheral T-cell lymphoma (VALENTINE-PTCL01): a multicentre, open-label, single-arm, phase 2 studyPier Luigi Zinzani, Koji Izutsu, Neha Mehta-Shah, et al.Clinical Lymphoma, Myeloma & Leukemia|December 26, 2024
A Phase I Study of Romidepsin in Combination With Gemcitabine, Oxaliplatin, and Dexamethasone in Patients With Relapsed or Refractory Aggressive Lymphomas Enriched for T-Cell LymphomasNicole Foley, Peter A Riedell, Nancy L Bartlett, et al.Journal of Plastic, Reconstructive & Aesthetic Surgery : JPRAS|February 4, 2020
Risk of breast implant associated anaplastic large cell lymphoma (BIA-ALCL) in a cohort of 3546 women prospectively followed long term after reconstruction with textured breast implantsPeter G Cordeiro, Paola Ghione, Andy Ni, et al.Journal of the American Academy of Dermatology|September 10, 2019
Outcomes and prognostic factors in African American and black patients with mycosis fungoides/Sézary syndrome: Retrospective analysis of 157 patients from a referral cancer centerShamir Geller, Emily Lebowitz, Melissa P Pulitzer, et al.Journal of the American Academy of Dermatology|September 27, 2008
Indolent primary cutaneous B-cell lymphoma: experience using systemic rituximabAnjali V Morales, Ranjana Advani, Steven M Horwitz, et al.Clinical Lymphoma, Myeloma & Leukemia|May 14, 2023
Bendamustine/Rituximab Plus Cytarabine/Rituximab, With or Without Acalabrutinib, for the Initial Treatment of Transplant-Eligible Mantle Cell Lymphoma Patients: Pooled Data From Two Pilot StudiesDilan A Patel, Fei Wan, Kathryn Trinkaus, et al.Pageof 23